Invention Grant
US07829319B2 Glutamic acid-modified classical swine fever virus autoproteases Npro
有权
谷氨酸改性古典猪瘟病毒自体蛋白酶Npro
- Patent Title: Glutamic acid-modified classical swine fever virus autoproteases Npro
- Patent Title (中): 谷氨酸改性古典猪瘟病毒自体蛋白酶Npro
-
Application No.: US11919346Application Date: 2006-04-25
-
Publication No.: US07829319B2Publication Date: 2010-11-09
- Inventor: Florian Werther , Clemens Achmüller , Philipp Wechner , Bernhard Auer , Silvio Podmirseg
- Applicant: Florian Werther , Clemens Achmüller , Philipp Wechner , Bernhard Auer , Silvio Podmirseg
- Applicant Address: CH Basel AT Vienna
- Assignee: Sandoz AG,Boehringer Ingelheim RCV GmbH & Co KG
- Current Assignee: Sandoz AG,Boehringer Ingelheim RCV GmbH & Co KG
- Current Assignee Address: CH Basel AT Vienna
- Agency: Birch, Stewart, Kolasch & Birch, LLP
- Priority: GB0508434.8 20050426; GB0508435.5 20050426; GB0605379.7 20060316
- International Application: PCT/AT2006/000165 WO 20060425
- International Announcement: WO2006/113957 WO 20061102
- Main IPC: C12N9/50
- IPC: C12N9/50 ; C12N15/70 ; C12N15/74 ; C12P21/06 ; C12N15/57 ; C12N15/62

Abstract:
The invention relates to a process for the recombinant production of a heterologous polypeptide of interest by cultivating a bacterial host cell transformed with an expression vector comprising a nucleic acid molecule encoding a fusion polypeptide wherein (a) the amino-proximal fusion partner is an autoprotease Npro comprising the replacement(s) by glutamic acid of one or more cysteines at positions corresponding to the positions 112, 134, and 138 of the autoprotease Npro of classical swine fever virus and (b) the carboxyl-proximal fusion partner is an heterologous polypeptide of interest fused to the autoprotease Npro so that it is capable of being cleaved from the fusion polypeptide by autoprotease Npro autoproteolytic activity, said process comprising (i) cultivating the transformed host cell under conditions permitting the expression of the fusion polypeptide and the formation of corresponding cytoplasmic inclusion bodies, (ii) isolating the inclusion bodies from the host cell, (iii) solubilizing the isolated inclusion bodies, (iv) inducing autoproteolytic cleavage of the heterologous polypeptide of interest from the fusion polypeptide, and (v) isolating the cleaved heterologous polypeptide of interest.
Public/Granted literature
- US20100062490A1 Organic Compounds Public/Granted day:2010-03-11
Information query